Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 155

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1B
Chunk 155
---

    (4,673
    )

    (3,606
    )

    Other long-term liabilities

    (43
    )

    1

    Net cash used in operating activities

    (61,289
    )

    (69,525
    )

    CASH FLOWS FROM INVESTING ACTIVITIES:

    Purchase of property and equipment

    (41
    )

    (206
    )

    Proceeds from sales of property and equipment

    148

    —

    Purchases of marketable securities

    (88,855
    )

    (164,988
    )

    Maturities of marketable securities

    146,324

    236,232

    Net cash provided by investing activities

    57,576

    71,038

    CASH FLOWS FROM FINANCING ACTIVITIES:

    Proceeds from issuance of common stock

    108

    253

    Net cash provided by financing activities

    108

    253

    NET (DECREASE) INCREASE IN CASH

    (3,605
    )

    1,766

    Cash, cash equivalents and restricted cash at beginning of year

    12,575

    10,809

    Cash, cash equivalents and restricted cash at end of period
     
    $
    8,970

    $
    12,575

    Reconciliation of cash, cash equivalents and restricted cash:

    Cash and cash equivalents
     
    $
    7,205

    $
    10,810

    Restricted cash

    1,765

    1,765

    Total cash, cash equivalents and restricted cash
     
    $
    8,970

    $
    12,575

    Supplemental schedule of non-cash investing and financing activities:

    Purchases of property and equipment included in accounts payable and accrued liabilities
     
    $
    —

    $
    152

    Right of use assets obtained in exchange for operating lease obligations
     
    $
    6,402

    $
    —

See accompanying notes to the consolidated financial statements. 

92

BOLT BIOTHERAPEUTICS, INC. 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

1. Description of the Business Bolt Biotherapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing novel immun